Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis
Abstract Few studies have reported that venetoclax, a selective BCL2 inhibitor, has shown promising efficacy in relapsed/refractory AL amyloidosis (RRAL), especially among patients harboring t(11;14). We retrospectively reviewed 29 RRAL patients treated with venetoclax between July 2022 and January...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer
2025-11-01
|
| Colecção: | Annals of Hematology |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1007/s00277-025-06716-0 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|